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Drug addiction is a chronic, relapsing disorder defined by cyclic patterns of compulsive drug seeking and taking interspersed
with episodes of abstinence. While genetic variability may increase the risk of addictive behaviours in an individual, exposure to
a drug results in neuroadaptations in interconnected brain circuits which, in susceptible individuals, are believed to underlie the
transition to, andmaintenance of, an addicted state. These adaptations can occur at the cellular, molecular, or (epi)genetic level and
are associated with synaptic plasticity and altered gene expression, the latter being mediated via both factors aﬀecting translation
(epigenetics) and transcription (non coding microRNAs) of the DNA or RNA itself. New advances using techniques such as
optogenetics have the potential to increase our understanding of the microcircuitry mediating addictive behaviours. However,
the processes leading to addiction are complex and multifactorial and thus we face a major contemporary challenge to elucidate
the factors implicated in the development and maintenance of an addicted state.
1. Introduction
1.1. Impact of Drug Addiction on Society. Drug addiction is
a serious socioeconomic problem associated with significant
mortality and morbidity. Recent estimates suggest that in
2009 as many as 271 million people participated in drug
use at least once worldwide, reflecting nearly 1 in 20
people aged between 15–64 years of age [1]. However these
numbers do not include the use of 3,4-methylenedioxy-
N-methylamphetamine (MDMA or ecstasy), hallucinogens,
and inhalants suggesting this figure could be substantially
higher. Results from the 26,000 people aged 12 years or
older who participated in the 2010 National Drug Strategy
Household Survey conducted by the Australian government
indicated that 15.1% of people smoked daily, 7.2% consumed
alcohol with 20–28% of these drinking at levels that would be
considered harmful, 10.3% used cannabis, 4.2% used phar-
maceuticals for nonmedical purposes, 2.1% used cocaine,
and 1.4% used hallucinogens [2]. Drug use of these pro-
portions places a great burden on society. Within Australia
smoking equates for 7.8% of the burden of disease, alcohol
consumption up to 3.8% and 2% for illicit drug use [3] with
an estimate of over $56 billion in economic drug associated
costs (approximately 56% for tobacco, 27% for alcohol, and
15% for illicit drugs) in 2004 to 2005 alone [4]. Of this,
nearly $31 billion relates to tangible costs (expenses, wages)
and $25 billion to intangible costs (diminished quality of
life). Together this more than triples the costs of cancer and
cardiovascular disease combined [5, 6]. Furthermore, it is
estimated that drug-related issues consume up to 3.5% of
the gross domestic product in western countries [7], which
is equivalent to $485 billion in the United States of America
alone [8]. There is also an association between drug use and
psychotic episodes, violence and aggression, mood disorders,
depression, paranoia, and suicide, which adds significantly
to society’s burden. What is more these figures also fail to
account for the impact upon the user’s family and friends.
1.2. Definition of Drug Addiction. Drug addiction, relating
to both licit and illicit substances, is a chronic, relapsing
disorder defined as compulsive drug seeking and taking
that continues despite significant negative consequences [9].
Addictive behaviours usually begin with a period of experi-
mentation with a particular drug, the use of which escalates
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over repeated exposures associated with the appearance of
tolerance; that is, an individuals’ hedonic (pleasure) set point
increases and increasing amounts of the drug are needed to
reach the “high” produced by earlier lower quantities (see
[10]). As an individual heads towards dependence, there is
an increase in the motivation to obtain and continue using
a drug and a loss of control in limiting drug intake. There
is also a growing awareness of the emotional consequences
associated with drug use and a link to environments
associated with accessing or taking the drug [11]. Following
chronic drug use, many individuals go into withdrawal,
usually through self-imposed abstinence, which may see the
development of withdrawal syndromes in some patients [12].
Withdrawal is also often associated with a negative emotional
state with individuals displaying high levels of depression,
stress, and anxiety. In themajority of individuals (up to 90%)
this is followed by relapse [13] resulting in a repetitive, cyclic
drug taking pattern which displays a high degree of resistance
to cessation of drug seeking (see [14]). Consequently, the
progression from casual drug use to an addicted state is
commonly referred to as the cycle of addiction which consists
of 4 main stages: (1) preoccupation and anticipation of
the drug, (2) intoxication, usually in a binge-like fashion
with loss of control, (3) withdrawal, usually associated with
negative aﬀect, and (4) craving generally followed by relapse.
However, not all individuals who experiment with drugs
of abuse go on to become addicted, indeed it is estimated that
only 15–20% of individuals who engage in drug taking will
meet the criteria for dependence (see [1]). Furthermore, an
individual’s vulnerability to displaying addictive behaviours
is highly complex and multifactorial being influenced by
(epi)genetic, biological, and environmental factors [15, 16].
As a result, individuals who go on to display characteristic
addictive behaviours may be influenced by factors mediating
their vulnerability to initiate and engage in drug use which
is further influenced by factors that mediate their shift from
casual to compulsive drug use [15]. Addiction also involves
components of both compulsivity and impulsivity; for exam-
ple, premature responding, as a measure of high impulsivity
on attentional tasks, is associated with cocaine seeking and
relapse [17].While drug use is associated with high impulsiv-
ity in humans [18] and may further exacerbate the impulsive
nature of an individual [19], evidence from human studies
suggests that trait impulsivity may play a greater role in
the influence over an individual’s predisposition to continue
drug-seeking and -taking behaviours [20]. This includes
resistance to ceasing these behaviours during abstinence as
drugs known to reduce impulsivity may aid in the prevention
of relapse [21]. Assessment of impulsivity in children and
adolescents has been used to predict subsequent alcohol-
related issues and drug use [22] and smoking vulnerability
[23], with analysis of high impulsivity in siblings of cocaine
users suggesting a heritable basis [20]. Impulsivity is also
thought to precede compulsivity and it is the shift from
impulsive to compulsive behaviours that is linked to the
development of addiction in many individuals (see [24]).
Impulsivity can also be distinct from other behaviours such
as anxiety, response to a novel environment, and some forms
of stress response [25]. However trait impulsivity appears to
play greater role in the loss of control over some drugs such
as cocaine compared to heroin, for example [26, 27].
Due to the complex nature of drug addiction, our greatest
understanding of the neurobiological aspects of processes
mediating addictive behaviours have, to date, largely come
from preclinical studies in animal models. Both humans and
animals will voluntarily consume drugs of abuse and display
preferences for environments associated with exposure to a
drug, continued motivation to obtain a drug, an inability
to limit or stop taking a drug despite adverse consequences,
and a high incidence of relapse following withdrawal [28].
Animal models can also be assessed based on genetic
variability, which indicates an association of heritable factors
such as impulsivity, with the predisposition to engage in
drug-seeking behaviours as seen in the human situation [24].
Of relevance, like humans, only a subset of animals exposed
to a drug (∼17%) will display addictive-like behaviours [28]
providing validity in the extrapolation of animal data to the
human situation.
This paper will provide an overview of the current
knowledge base of the complex mechanisms mediating
addictive behaviours, incorporating the literature from both
human studies and preclinical animal models. Rather than
in-depth exploration of any one topic, it will highlight the
key processes that are believed to drive continued drug
use by presenting specific examples of the neuroadaptive
changes that exist following acute exposure to a drug and
how these may diﬀer following repeated exposures and
following periods of withdrawal. The paper will also explore
the molecular and cellular mechanisms linked to substance
abuse with a particular focus on genetics, epigenetics and
noncoding RNAs, and the recent advances in our understat-
ing of their role in addiction. Finally, the paper will introduce
the concept of optogenetics and highlight how this technique
may be of value to addiction neuroscience.
1.3. Circuits and Neurotransmitters. There are many diﬀerent
drugs that are commonly abused in society, some being
obtained legally such as alcohol, tobacco, and inhalants
while others are obtained illegally, such as marijuana,
amphetamine, cocaine, and heroin. Each drug has a diﬀering
chemical and pharmacological profile, can be administered
via diﬀerent routes, acts on diﬀerent neurobiological systems,
and undergoes diﬀerent metabolic pathways [29]. Never-
theless, all drugs appear to exert their initial eﬀects on the
mesocorticolimbic dopaminergic pathway which is heavily
involved in reinforcement learning [30]. Originating from
dopaminergic neurons located in the ventral tegmental area
(VTA) of the midbrain this pathway projects to the nucleus
accumbens (NAcc) (motivation), amygdala (mediates asso-
ciation of reward with cues and negative reinforcement),
ventral pallidum, hippocampus (limbic system associated
with memory and learning), and forebrain, in particular
the prefrontal cortex (PFC). The acute exposure to a drug
results in a transient increase in the extracellular levels
of dopamine in the NAcc [31] and other projection sites,
though the process via which this occurs may be dependent
on the drug itself. For example, for alcohol, nicotine, opiates,
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cannabis, and inhalants this occurs via enhancement of
dopamine release from presynaptic terminals primarily as a
consequence of increased neuronal firing in the VTA [32].
In comparison, for cocaine this occurs via the inhibition
of presynaptic dopamine uptake by the dopamine trans-
porter (DAT) or via actions on the vesicular monoamine
transporter which actively reverses DAT function to elevate
extracellular dopamine in the NAcc, which is the case for
amphetamine [33]. Following repeated exposure to a drug
there is a progressive increase in basal levels of dopamine
and the appearance of tolerance [34] along with altered
dopamine receptor expression [35]. Should exposure to the
drug cease, the levels of dopamine typically fall below normal
baseline levels. Conditioned cues associated with drug taking
can be suﬃcient to induce relapse and indeed these cues are
powerful enough to activate dopaminergic brain regions in
patients who regularly abuse cocaine [36].
However, the VTA contains a heterogeneous population
of cells with approximately 65% being dopaminergic, 30%
being gamma-aminobutyric acid (GABA)ergic, and 5%
being glutamatergic (see [37]). The primary aﬀerents to the
VTA are excitatory glutamatergic inputs from the PFC and
inhibitory GABAergic inputs from medium spiny neurons
(MSNs) in the NAcc, both of which can form feedback loops
to regulate activity in this region though this can occur via
diﬀerent mechanisms. Drug-induced release of GABA, for
example, may mediate local inhibitory feedback mechanisms
by binding presynaptically to receptors expressed by MSNs
themselves or enhance synaptic inhibition by binding postsy-
naptically at projection sites [38], thus causing disinhibition
of downstream targets. This includes increasing dopamine
release, as the firing rate of VTA neurons is under inhibitory
control [39]. The VTA also receives connections from regions
such as the ventral pallidum, hippocampus, amygdala, lateral
hypothalamus, and bed nucleus of the stria terminalis [40,
41].
Aside from the VTA, the NAcc is believed to play a
substantial role in mediating addictive behaviours [42, 43].
The NAcc is involved in the control of the motivational
value of stimuli [44], reward reinforcement [45], and the
mediation of impulsive choice [46]. As well as dopaminergic
inputs from the VTA, the NAcc also receives excitatory
glutamatergic input from the PFC, amygdala, thalamus, and
hippocampus thus serving as an interface between the limbic
(processing of new and learnt information) and motor (task
performance) pathways. Furthermore MSNs, the dominate
cell type in the NAcc, can express either dopamine D1
receptors and thus form part of the direct pathway that
results in neuronal excitation or D2 receptors and thus
form part of the indirect pathway that results in neuronal
inhibition [47, 48]. Consequently, the activation of these
receptor subtypes and thus modulation of the direct and
indirect pathways determine which signals are reinforced and
which are suppressed [49]. More recently human functional
neuroimaging studies have identified that the PFC plays
an important role in addiction [50]. This is thought to
occur, in part, via the PFCs ability to regulate the activity of
neurons in reward associated nuclei (i.e., the NAcc and VTA)
and its involvement in inhibitory control over behaviour,
planning, and executing complex cognitive behaviours and
executive function (i.e., awareness, decisionmaking, and self-
control) [50]. The PFC is also believed to play a pivotal
role in mediating controlled drug intake with a transition
from PFC to striatal control as drug use transfers into
a compulsive behaviour (see [51]). However, the highly
integrated networks mediated by exposure to a drug of abuse
and the diﬀerent neurotransmitter systems they may act
upon permit considerable crosstalk which acts to fine tune
signal transmission, with the resultant outcome being driven
by an integration of all incoming signals.
2. Neuroadaptations and Addiction
2.1. Plasticity. There are many ways to investigate drug-
related processes in animal models, one of the most common
being via a self-administration paradigm. This paradigm
requires an animal to perform a task, such as pressing a
lever, which results in access to a drug. This motor task is
normally associated with a conditioned stimulus, such as
a light cue, that becomes associated with the drug reward.
The conditioned stimulus is used to mimic the eﬀects of
environmental associations with drug use that exist in drug
addicted humans. This model can be used to assess diﬀerent
components of addictive behaviours including spontaneous
initiation of drug taking, motivation, persistence and relapse,
and the neural pathways mediating these responses (see
[52]). Using self-administration paradigms, studies like
those by Porrino et al. have reported that the functional
activity in the brain of rhesus monkeys self-administering
cocaine is altered when compared to those receiving a food
reward. Initially activity is noted in regions mediating moti-
vation and reward, such as the ventromedial PFC and ventral
striatum, which extends to regions involved in emotion and
cognitive processing upon extended repeated exposures (100
sessions) [53]. Of interest, in this study the changes in
functional activity induced by exposure to cocaine were still
present after one month of abstinence suggesting that drug-
induced plasticity and long-term adaptations had occurred.
These data support reports from human studies of patients
with drug addictions where the structures contributing to the
corticostriatal system are abnormal on magnetic resonance
imaging (MRI) scans which is subsequently associated
with altered behavioural performance in these individuals
[54].
As not all individuals who engage in drug use become
addicted, it is believed that, in the subset of individuals who
do become addicted, exposure to a drug is suﬃcient to result
in neuroadaptive changes to drug sensitive pathways in the
brain that extend beyond the initial neuropharmacological
actions of the drug. Following subsequent exposures these
neuroadaptations, at either the cellular, synaptic, molecular
or (epi)genetic level, lead to altered behaviour and the driv-
ing force to continue drug-seeking and -taking behaviours
(see [41, 55]). Examples of the mechanisms mediating
one of the commonest forms of drug-induced neuroad-
aptive change, that is, synaptic plasticity, are highlighted
below.
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2.2. Synaptic Plasticity. Drugs of abuse are able to induce
either pre- or postsynaptic plasticity, a process which is
mediated in an activity-dependent manner. This can occur
via changes to synaptic structures themselves, via eﬀects on
signal transduction, or at the level of receptor expression, all
of which have the potential to lead to synaptic rearrangement
and altered neuronal signaling.
2.2.1. Dendritic Spines. Changes to the density and mor-
phology of dendritic spines is a commonly reported neu-
roadaptation following exposure to a drug of abuse or
during withdrawal itself. Golgi-Cox staining has illustrated
a significant increase in the density and a 2.6-fold increase
in branching of dendritic spines of MSNs in the shell of
the NAcc following abstinence from cocaine for one month
after one month of self-administration in rats [56]. A similar
change is observed at pyramidal cells in the PFC and
parietal cortex. Changes to dendritic spines may be specific
in nature. Kim et al. have shown that cocaine repetitively
injected into transgenic mice expressing green fluorescent
protein under the control of promoters for either D1 or D2
receptors results in a selective increase in spine density for
MSNs expressing D1 but not D2 [57]. This correlates with
decreased membrane excitability in these neurons, with no
corresponding change observed in D2 expressingMSNs. This
highlights that neurons within the same cell population may
diﬀerentially contribute to a drug-induced neuroadaptation.
Drug-induced changes to dendritic spines may also occur via
separate but interactive signaling pathways resulting in more
than one structural alteration [58] having the potential to
cause regional, compartmental, or type-specific changes to
dendritic spines themselves [59].
2.2.2. Neurotrophic Factors. The neurotrophin brain-derived
neurotrophic factor (BDNF) and its interactions with TrkB
receptors (its primary receptor) are believed to play an
important role in drug-induced neuroadaptive changes and
therefore addictive behaviours [60–62]. Cocaine-dependent
individuals have high serum levels of BDNF which have been
found to be predictive for increased risk of relapse following
a period of abstinence up to 90 days [63], with elevated levels
being maintained up to 6 months into abstinence in prior
alcohol-dependent patients [64]. Furthermore, in animal
models, there is a progressive increase in the levels of BDNF
in reward-associated nuclei (VTA, NAcc, and amygdala)
during 60 days withdrawal from cocaine, which is associated
with incubation of craving (see below) in these animals
[65]. Levels of BDNF in the NAcc have also been linked
to enhancement of locomotor activity, conditioned place
preference (CPP), and reinstatement following cocaine [66].
Drug-induced changes to BDNF levels in mice occur in a
time-dependent manner, occurring in the NAcc prior to the
VTA [60]. The authors suggest that time-dependent increases
in BDNF may lead to synaptic modifications that enhance
cue-induced reinstatement following extended periods of
withdrawal and implicate BDNF in persistent drug-seeking
behaviours, at least for cocaine [67]. Both the levels of BDNF,
the density of dendritic spines are altered following exposure
to ethanol in rats [68] and it is the changes to BDNF that are,
in part, believed to mediate changes to dendritic spines as
BDNF can be locally synthesized within the spine itself [69].
In vitro experiments in cultured rat hippocampal neurons
have shown that exposure to BDNF activates TrkB leading to
downstream signaling cascades and the promotion of neurite
elongation, and enlargement of the head of dendritic spines
[70]. Should TrkB activation be sustained subsequent neurite
branching and neck elongation are observed.
2.2.3. Signal Transmission. BDNF/TrkB interactions also
enhance basal levels of long-term potentiation (LTP) in cul-
tured hippocampal neurons [70]. This suggests that BDNF
may also play an important role in modulating activity-
dependent signal transmission between neurons [71]. There
are two markers of long-term activity-dependent signal
transmission, either LTP or long-term depression (LTD). LTP
refers to an enhancement of signals between neurons and is
associated with an increase in synaptic strength. In contrast,
LTD refers to a suppression of signals between neurons and
is associated with the weakening and elimination of synapses.
Consequently, it is the combined actions of LTP and LTD that
refine and consolidate adaptive changes to neuronal circuits
[72, 73]. Both LTP, and more recently LTD are emerging as
key players in the mediation of addictive behaviours.
2.2.4. LTP. A single acute exposure to cocaine in rat slice
preparations is suﬃcient to induce LTP at glutamatergic
synapses in the VTA [74] and repeated inductions of LTP
leads to synaptic enhancement [75]. After 3 inductions of
LTP, via exposure to glutamate each 24 hours apart, there are
long-lasting and time-dependent changes to the expression
of synapse-related genes occurring at either 24–96 hours
or 6–12 days after the last exposure [76]. Interestingly, in
dopaminergic neurons, exposure to cocaine inverts the pro-
cesses that lead to the generation of LTP from depolarization
to hyperpolarization [77]. Self-administration studies have
shown that drug-induced potentiation, the eﬀects of which
were greater for cocaine over natural food rewards, persists
during abstinence for up to 3 months [78]. The same eﬀects
are not observed if cocaine is passively infused suggesting
that the drug itself is insuﬃcient to induce this change and
that associated cues play a role in these adaptations. Drugs
also appear to alter the ability to subsequently modulate
signal transmission as during withdrawal from cocaine
there is an inability to develop further LTP and LTD in
the NAcc after stimulation of the PFC [79]. The authors
show that this eﬀect can be restored by application of N-
acetylcysteine, which increases glutathione synthesis thus
activating the cystine-glutamate exchanger and restoring
glutamate homeostasis.
2.2.5. LTD. There is also growing evidence that long-term
impairments in LTD may play a role in the maintenance of
an addicted state. In animals that are sensitized to cocaine
there is long-lasting depression at excitatory synapses made
by PFC aﬀerents onto MSNs in the NAcc shell [80]. However
LTD does not appear to be impaired during the initial phase
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of learning in a cocaine self-administration paradigm, but
once learning has been consolidated, LTD is suppressed [81]
and remains suppressed in the NAcc even during the initial
stages of abstinence [82]. In animals that do not display the
hallmarks of addiction deficits in LTD progressively recover
even though these animals maintain a controlled drug intake.
However in animals that do display behavioural hallmarks
of addiction LTD remains suppressed [81]. The same group
has gone on to show that this eﬀect can be related to LTD
mediated by stimulation of specific receptor subtypes (endo-
cannabinoid mediated versus glutamatergic) in the PFC
[83]. In rats, blocking LTD at glutamatergic synapses in the
NAcc is suﬃcient to prevent the expression of amphetamine-
induced behavioural sensitization [84]. A single presentation
of both the N-methyl-D-aspartic acid (NMDA) receptor
antagonist 2-amino-5-phosphonovalerate and the group
I/II metabotropic glutamate receptor (mGluR) agonist 1-
aminocyclopentane-1,3-dicarboxylic acid is suﬃcient to
stimulate a transient LTD, which normalises within 24
hours [85]. However, repeated inductions of LTD lead to
a persistent decrease in excitatory postsynaptic potentials
and the number of synaptic structures. In support of these
observations, Egashira et al. have shown that 3 inductions
of LTD lead to reduced synaptic strength and the number of
pre- and postsynaptic structures. This process requires rapid
novel protein synthesis (within 6 hours) [86] the eﬀects of
which can last up to 14 days after the last induction [87].
Consequently LTD is also believed to play a role in relapse,
which may be dependent on the nature of how the drug is
removed. Both straight withdrawal and extinction training
(see below) following cocaine self-administration result in
reduced LTP in the NAcc following stimulation of the PFC,
though only extinguished animals have blunted LTD [88].
2.2.6. Receptor Expression. Drugs of abuse may either
increase or decrease the expression of receptors on cells
or their processes [89], with subsequent changes occurring
during periods of abstinence [90], in a dose-dependent and
region-specific manner [90]. Cocaine-related fatalities have
been associated with an increase in the mRNA for dopamine
D3 receptors in the NAcc [91] while in drug abusers with a
history of cocaine use, heroin use, or both, there is a strong
positive correlation between the expression of mRNA for
the A1 subunit of amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA) glutamate receptors and scaﬀolding
proteins such as the post-synaptic density protein-95 in
the amygdala [92]. The authors argue that this response is
indicative of strengthening of synapses in this region. In
animal models, acute exposure to cocaine can transiently and
rapidly reduce the expression of mGluRs in the striatumwith
levels returning to normal by 6 hours after exposure and no
associated change in the PFC or hippocampus [93]. In the
VTA, AMPA GluA1 subunits are decreased following acute
exposure to cocaine in mice but only in the parabrachial
region [94], in the paranigral region of the VTA the surface
expression of these receptors is increased. Following 14 days
exposure to cocaine, these responses are diminished in both
regions but only for dopaminergic processes, in comparison
GluA1 subunits on GABAergic processes display region-
specific changes [94]. In both rats and mice after 3 weeks
of withdrawal following repeated cocaine administration for
7 days there is an increase in both NMDA GluN2B and
mGluR1a receptors in the PFC, while diﬀerent subunits of
these receptors (GluN2A and mGlu1) are increased in the
hippocampus [90]. The NMDA GluN2A subunit is also
increased in the dorsal striatum but mGluR levels are not
altered, and all 3 subunits (NMDA GluN2A, 2B, and mGlu1)
are reduced in the shell of the NAcc.
The ability to understand the complex nature of receptor-
mediated adaptive changes following exposure to a drug
is further heightened by the fact that receptors may be
activated by more than one mechanism and/or ligand and
may form oligomeric complexes with other receptors in
a region-specific manner [95]. For example, some sub-
types of mGluRs (i.e., mGlu1, mGlu3, and mGlu5) are
responsive to not only glutamate (a neurotransmitter) but
also extracellular levels of calcium (a divalent cation) [96].
This occurs via partially overlapping binding sites, with
increasing calcium levels resulting in a greater prolongation
of glutamatergic responses [97]. In cells mutation of the
binding site for glutamate leaves calcium signalling intake;
however, inhibiting calcium binding via similar methods
reduces the sensitivity to both calcium and glutamate [98]
indicating that functional calcium signalling is required for
eﬃcient glutamate signalling in some cases. It is hypothesised
that these receptors work synergistically to yield a maximal
eﬀect so that the activities of downstream messenger systems
mediating functions such as LTP are maintained.
Heterooligomeric complexes have been shown to exist
between dopamine D2 and mGlu5 receptors [99], mGlu5
and NDMA receptors [100], serotonin (5-HT)2A and mGlu2
receptors [101], and mGlu5 and GABA(A)α1 receptors [102]
as well as other combinations including adenosine A2A
[103], μ-opioid [104], or estrogen [105]. Recent evidence by
Cabello et al. also suggests that higher order oligomers also
exist. Using biomolecular fluorescence complementation,
bioluminescence resonance energy transfer and sequen-
tial resonance transfer techniques complexes containing
dopamine D2, mGlu5, and the adenosine A2A receptors have
been identified [106]. All 3 receptors are physically linked
in the cell membrane and are expressed on post-synaptic
dendritic spines of GABAergic striatopallidal neurons [106].
The presence of heteromeric complexes and higher-
order oligomers aids in the explanation of the ability of
a single neurotransmitter to activate and independently
regulate several diﬀerent pathways even though the receptors
may be from diﬀerent families [107]. This leads way to
the possibility of synergistic and antagonistic interactions of
diﬀerent ligands at the one site to facilitate neurotransmitter
release and induce synaptic plasticity in response to a drug
of abuse. For example, perfusion of the mGlu5 agonist (RS)-
2-chloro-5-hydroxyphenylglycine (CHPG) into the NAcc
increases GABA release in the ventral pallidum [108]. This
response can be potentiated by administration of CGS
21680, an adenosine A2A agonist, and counteracted by
coinfusion of quinpirole, a dopamine D2 agonist. These
receptor complexes may also work synergistically to produce
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their resultant eﬀects. Coadministration of subthreshold
doses of the mGlu5 allosteric antagonist 3-((2-methyl-4-
thiazolyl)ethynyl)pyridine (MTEP) and the adenosine A2A
antagonist SCH58261 is suﬃcient to reduce ethanol respond-
ing and cue-induced reinstatement of ethanol seeking [109].
The same eﬀects are not observed when administered alone
or if these drugs are combined with 8-cyclopentyl-1,3-
dipropylxan (DPCPX), an adenosine A1 antagonist sug-
gesting subtype receptor specificity of these interactions.
Furthermore, costimulation of the adenosine A2A andmGlu5
receptors results in a synergistic eﬀect on extracellular
signal-regulated kinase 1/2 (ERK) phosphorylation and cFos
expression [103]. While the authors did not observe a syner-
gistic eﬀect at the level of second messenger systems in this
study, others have used mice neostriatal slices to show that
synergistic responses do occur at this level which potentiates
the formation of 3′-5′-cyclic adenosine monophosphate
(cAMP) and increases phosphorylation of the signal trans-
duction molecule dopamine- and cAMP-regulated phospho-
protein of 32,000 kDa (DARPP-32) involved in dopaminergic
signalling [110].
2.3. Impact of Drug Induced Neuroadaptations. As a result of
the above-mentioned processes, drug-induced neuroadapta-
tions alter homeostatic set points and thus the ability of the
brain to function “normally”, reducing the ability to process
the adverse consequences of drug taking. Neuroadaptations
also play a role in the lack of flexibility in the control
over addictive behaviours which results in a window of
opportunity before drug-related behaviours switch from
goal-directed actions that are still sensitive to devaluation
to habitual-based responses [51, 111]. This corresponds to
a neuroadaptive shift in the brain regions mediating these
responses. Consequently neuroadaptations are believed to
underlie the switch from voluntary controlled drug use
to habitual, compulsive drug use and the maintenance of
drug-seeking behaviours. They appear stable and persistent
and are linked to the high incidence of relapse following a
period of abstinence (for reviews see [72, 73]). Drug-induced
neuroadaptations are also believed to lead to “incubation
of craving”, a complex phenomenon where drug-seeking
behaviours increase over time being associated with not only
exposure to the drug but also drug-associated cues. This
phenomenon has been shown in animal models were the
responsiveness to drug-paired cues progressively increases
[65, 112]. For example, in rats responding for cocaine in
a self-administration paradigm is significantly increased by
day 7, compared to the first day, of abstinence following only
10 days of prior exposure, which progressively increases over
60 days of abstinence [112] and is maintained for up to 100
days of abstinence [113].
Drug-associated cues can potently drive relapse during a
period of abstinence [114]. Consequently it is hypothesized
that abstinence alone is insuﬃcient to reverse drug-induced
adaptations suggesting a persistent alteration of neuronal
plasticity. Indeed prior exposure to a drug may actually
be suﬃcient to inhibit the ability of stimuli to induce
subsequent neuroadaptive changes [79, 115]. In this regard,
there is growing evidence in animal models of the eﬀec-
tiveness of extinction training over withdrawal paradigms
in maintaining abstinence [116]. During extinction training
drug-seeking actions do not yield a drug reward, removing
the adaptive value of drug seeking (comparable to cue
exposure therapy during rehabilitation in humans) (see
[117]). As extinction training results in altered molecular
mechanisms that are not observed following abstinence
alone [88], it appears that old behaviours remain intact
and are not simply “unlearned”, rather new pathways and
subsequently contextual behaviours need to be acquired in
order to maintain abstinence [118]. In both human and
animal studies, the eﬀectiveness of extinction training can be
enhanced via the incorporation of active retrieval of drug-
associated memories prior to a training session [119]. In this
manner the brain needs to form new adaptations and learn
newmemories other than those associated with drug-seeking
and -taking behaviours that consolidate the experience of
“no drug”. However extinction training does not appear
eﬀective in altering the enhanced LTP observed following
exposure to cocaine which persists in the VTA after 3 weeks
of abstinence and following cue-induced reinstatement and,
thus even when drug-seeking behaviours are extinguished,
neurotransmitter function remains potentiated (at least for
glutamatergic processes), potentially driving drug-seeking
behaviours [78].
3. Genes and Addiction
3.1. Genetic Links to Dependence. Addiction is a complex
disease that is multifactorial and polygenic, thus it does not
follow a clear Mendelian pattern of gene expression. Unlike
disorders such as Down’s syndrome, no single gene has been
identified that predisposes individuals to develop addictive
behaviours. However, genetic background is believed to
influence addiction liability with mutations in certain genes
believed to increase an individual’s vulnerability to addictive
behaviours should they engage in drug use (see [120]).
Twin and adoption studies indicate the heritability of genes
that predispose an individual to becoming addicted ranges
from 40% to 70% (alcohol: 50%, cocaine 60%, and opiates
70%) [121]. That is up to 70% of the risk for addictive
behaviours can be attributed to heritable influences, with
a 4–8-fold increase in the risk of developing an addictive
behaviour if a first-degree relative has a substance abuse
disorder (see [122]). To date 1,500 genes have been linked
to an “addiction” phenotype in humans [123] which can
further be classified as those related to the initial stages of
experimentation, those related to neuroadaptations follow-
ing continued exposure, and those that influence outcome
including the age of onset and patterns of use. The influence
of genetic background over addiction appears additive;
the more mutations an individual has, the greater their
vulnerability to becoming addicted with diﬀerent genes
contributing to addictive behaviours in diﬀerent individuals
is (see [124]). However environment may also exert consid-
erable influence over the development of addiction, which
is further confounded by gene-environment interactions
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[125]. Many psychiatric disorders including depression,
stress, and anxiety coexist with substance abuse disorders,
as such heritable factors that influence these disorders may
be perpetuated by adverse environmental exposures which
may act as a trigger to activate a genetic predisposition and
influence behavioural outcome, that is, it increases the risk of
substance use (see [122]).
The most common and best understood eﬀects to
the genetic sequence occur at the level of a change to
a single nucleotide in a gene (SNP—single nucleotide
polymorphism). There is growing evidence that SNPs have
the potential to influence addictive behaviours, especially
for alcoholism. SNPs in genes for the catalytic enzymes
for alcohol metabolism including alcohol dehydrogenase
1B (which oxidises ethanol to acetaldehyde) or aldehyde
dehydrogenase-2 (which converts acetaldehyde to acetate)
are suﬃcient to reduce the risk for alcoholism in some
populations [126]. Mutations in genes encoding the NMDA
GluN2A subunit (Schumann et al., 2008), mGlu5 receptors
[127], or GABAA receptors [128] may lead to a higher risk of
developing alcohol dependence. Individuals with variations
in the genes for dopamine D2 receptors show younger onset
and severity of drinking [129]. SNPs in genes encoding for
the Y2 receptor for neuropeptide Y have been associated with
alcohol dependence, alcohol withdrawal, comorbid alcohol
use, and cocaine dependence [130]. In comparison, SNPs in
genes for neuropeptide Y5 receptors are only associated with
alcohol withdrawal in human studies [130]. See Dick and
Foroud for an extensive review on polymorphism associated
with alcoholism [124].
There is growing evidence that SNPs may also influence
other addictive behaviours beyond those for alcoholism. A
meta-analysis of the A1 allele frequency at the dopamine
D2 receptor in drug addicted compared to control patients
indicated an association with SNPs in this allele with alcohol,
nicotine, and opiate dependence, but not stimulant use dis-
orders [131]. Variants upstream of CHRNB4, which encodes
for the beta 4 subunit of neuronal nicotinic receptors,
have been linked to the age at onset for daily cigarette
smoking [132]. SNPs in the D1 gene (rs686) [133], D2
gene, though weak (rs7131056, rs4274224, rs4648318, and
rs6278) [134], and D3 gene (rs6280) [135] have also been
associated with increased nicotine dependence. While other
SNPs, including those in the dynamin 1 gene (rs3003609)
involved in the control of synaptic endocytosis, have been
associated with the extent of smoking (quantity and heav-
iness) [136]. Interestingly assessment of a similar SNP in
the gene for the dopamine D1 receptor was not associated
with methamphetamine abuse, though this and other studies
highlight the need for ethnic considerations when comparing
polymorphisms across racially diverse groups [137, 138].
SNPs in diﬀerent opioid receptors and peptides have also
been associated with diﬀerent drug phenotypes (see [139]
for extensive review). Val66Met polymorphisms for BDNF
are associated with a current or former history of smoking
[140] and the onset of heroin use [141], but not alcohol
dependence [142]. In mice, this polymorphism has been
shown to play a role in the extinction of cocaine responding
but not reinstatement [143].
While 5-HT appears as an emerging factor in regulating
addictive behaviours, associative studies in humans between
SNPs in genes for either 5-HT1B receptors [144] or the
gene for tryptophan hydroxylase (the rate limiting enzyme
for 5-HT synthesis) [145] have failed to be linked to
cocaine or alcohol dependence. However, polymorphisms
in the gene encoding the 5-HT transporter have been
linked to sociopathy in alcoholics, supporting a role for
5-HT in mediating drug-related aﬀective disorders [146].
Changes to the serotonergic system (either 5-HT levels or
receptor expression) following exposure to a drug have been
hypothesised to contribute to the high rate of aﬀective
disorders such as depression associated with drug abusers. It
is these aﬀective disorders which are thought to contribute
to 5-HT’s role in mediating drug-seeking behaviours with
deficits in 5-HT transmission during the early stages of
abstinence hypothesised to contribute to relapse in human
patients [147].
Together these findings provide insight into genetic
variability and its role in the manifestation of an addictive
behaviour. Thus they provide novel targets and a potential
short list of candidate genes to aid in refining treatment
strategies. However the interpretation of these findings
should not be over simplified. To date 31 SNPs for D1 recep-
tors alone have been identified (see [131]) making direct
linkages to aspects of addictive behaviours diﬃcult. Indeed
the relationship between SNPs and drug addiction is often
weak and unlikely to explain all complex behaviours associ-
ated with the disorder. Add to this the possibility of structural
variants (small rearrangements in the chromosome charac-
terised by deletion or insertion of up to 1000 bp) and copy
number variants (large rearrangements in the chromosome
characterised by deletion, duplication, or insertion of over
1 Kb), both of which have not been assessed in relation to
addiction, and the complexity increases several folds.
3.2. Gene Expression. Irrespective of the presence or absence
of genes that may increase an individual’s vulnerability to
become addicted, human postmortem studies have shown
that the expression of numerous genes is altered in the brain
of addicted patients [148]. Chronic cocaine use, for example,
diﬀerentially alters the expression of up to 49 transcripts in
the NAcc including those involved in signal transduction,
synaptic function, and DNA to RNA processing [149].
Similarly, significant upregulation of numerous transcripts,
including glutamate receptors, have been reported using
targeted microarrays on the VTA from cocaine overdose
victims [150]. Importantly changes to transcripts reported
following chronic cocaine use correspond to altered protein
expression in both of these studies [149, 150]. In support
of the observations in humans, up to 295 genes were
diﬀerentially regulated after 1 h of nicotine treatment in
cultured neuron-like SH-SY5Y cells, including those involved
in neural development, synaptic plasticity, neuronal survival,
immune responses, and cellular metabolism [151]. Indeed,
genes aﬀected by drugs of abuse can be subcharacterised into
those relating to the extracellular matrix, synaptic plasticity
and eﬃcacy, receptors, ion channels and transporters, signal
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transduction, and cell death, among others (see [152] for an
extensive list).
While drugs of abuse may alter gene expression, conse-
quently having impact on protein expression, the long-term
eﬀects are not fully understood. The mRNA for the immedi-
ate early genes cFos, Nr4a1, activity-regulated cytoskeleton-
associated protein, and early growth response protein 1
are reduced in the PFC and NAcc during withdrawal from
cocaine self-administration for 10 days in rats, the eﬀects
of which persist 100 days into withdrawal [113]. In contrast
the mRNA for the neuropeptides cocaine and amphetamine-
regulated transcript (CART) and neuropeptide Y were
significantly increased following the first day of withdrawal
only in the medial PFC. Chronic exposure to a drug
may have a diﬀerential eﬀect on the expression of these
genes; indeed some genes show a sensitized response and
others show desensitization. Furthermore, additional genes
that had not previously been responsive to cocaine may
show altered expression during abstinence [153]. Similar
diﬀerential changes are observed during abstinence on pro-
tein expression [154]. Irrespectively these changes have the
ability to aﬀect behaviour, for example, there is a persistent
downregulation of genes related to synaptic plasticity in the
striatum of animals that are vulnerable to relapse to cocaine
seeking [155].
Understanding the relationship of altered gene expres-
sion and its ability to mediate addictive behaviours is further
complicated by the possibility of gene splicing. As proteins
are not derived from continual sequences in the gene,
splicing occurs when diﬀerent exons of the RNA are recon-
stituted in diﬀerent ways thus producing diﬀerent isoforms
of the same protein. For example, the genes encoding BDNF
in rats can form 8 unique transcripts via slicing of four
5′ exons (exons I–IV) and one 3′ exon (exon V) [156],
though up to 8 exons may exist [157]. Each exon may be
diﬀerentially regulated to form distinct BDNF transcripts in
response to local stimuli, including neuronal activation, in
a developmental [158] and region-specific manner [159].
Furthermore, upon stimulus diﬀerent splice variants of
BDNF may be found in diﬀerent subcellular compartments,
including dendrites, in which they are not normally present
under basal conditions [160]. In human postmortem studies,
chronic cocaine use decreased the expression of BDNF4
and BDNF1 in the cortex, while it increased BDNF4 in the
cerebellum relative to noncocaine users [161]. In the adult
rodent brain all splice variants are expressed at high levels
in the hippocampus, with splice variants for BDNF4 and
5 also being high in the striatum [157]. There is a rapid
and dramatic (up to 4-fold) increase in the expression of
the mRNA for BDNF4 in the striatum and PFC following
acute exposure to cocaine; the splice variant for BDNF1
is also increased in cortex. However, the expression of all
splice variants is unaltered following chronic exposure to
cocaine for 10 days or following up to 3months of abstinence
[157]. This is in contrast to the observation that there is
a progressive increase in BDNF levels in reward-associated
nuclei (VTA, NAcc, and amygdala) over a prolonged 90-
day period of withdrawal after cocaine self-administration
[65], suggesting that additional factors may be acting to
regulate the translation of mRNA to protein. There is also the
possibility that SNPs in splice variants of a gene can influence
addictive behaviours. The mRNA for dopamine D2 receptors
exists as two splice isoforms, one of which is long (D2L)
and one of which is short (D2S), being expressed primarily,
but not exclusively, postsynaptically, and presynaptically,
respectively. Human postmortem studies have shown that
a history of cocaine is associated with 2 intronic SNPs
(rs2283265 and rs1076560) in D2S which leads to a reduction
in D2S and thus alters the D2S/D2L ratio in the PFC and
putamen [138].
Patterns of gene expression are regulated by transcription
factors which are transiently expressed to act locally to regu-
late gene expression at the cell in which they were initially
produced. Transcription factors are proteins which bind to a
specific DNA sequence to regulate the transcription of DNA
to mRNA, often acting to enhance or retard the activity of
enzymes such as RNA polymerase or molecules that regulate
acetylation of histones (see below). Two common transcrip-
tion factors associated with addiction are cAMP response
element binding (CREB) and members of the Fos family.
CREB is stimulated by initiation of the cAMP pathway in
response to activation of receptors or ion channels. This leads
to rapid yet transient CREB activation via phosphorylation
(pCREB) which binds to a cAMP response element region in
the DNA sequence and forms a complex with CREB-binding
proteins to subsequently regulate gene transcription. CREB
is expressed at high levels throughout the brain [162] and
targets genes including cFos, BDNF, tyrosine hydroxylase,
and several neuropeptides including corticotropin-releasing
factor and dynorphin.
Investigations into the role of CREB in mediating addic-
tive behaviours have shown that overexpressing CREB in
the NAcc alters drug-related behaviours including decreasing
the rewarding eﬀects of cocaine [163]. In contrast, increased
expression of CREB in the NAcc shell enhances the reinforce-
ment of cocaine self-administration in rats, independent
of learning the task, and the motivation to obtain drug,
the latter observation being correlated to modulation of
BDNF protein levels in the same region [45]. The same
group also showed in this study that increasing CREB in
the NAcc following a period of abstinence enhances drug-
primed reinstatement specifically but not cue- or stress-
induced relapse. CREB in the dorsal striatum has also been
linked to sensitivity to psychostimulants [164]. When mice
are exposed to nicotine in their drinking water for 50 days
the levels of pCREB are unaltered, however, after 24 hours
of withdrawal there is a diﬀerential response to pCREB
levels in reward associated nuclei [60]. In the NAcc the
expression of pCREB is increased which corresponds to
increased BDNF levels in this region, while in the VTA
the levels are decreased relatively to those during chronic
exposure to nicotine [60], the authors suggesting that this
reflects compensatory responses in an attempt to maintain
nicotine-induced adaptations in this pathway. The role of
CREB in corticostriatal processesmediating specific elements
of addictive behaviours should also be considered as con-
ditional ablation of CREB1 in the cortex and hippocampus
in mice decreases the motivation to self-administer cocaine,
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though animals still display a CPP and normal locomotor
responses [165].
The Fos family of transcription factors include cFos,
FosB, and ΔFosB (a splice variant of FosB) and represent
an immediate early gene family which are rapidly induced
following stimulation. They dimerise with proteins from the
JUN family to form the AP-1 complex which consequently
upregulates transcription. This complex can be activated via
either extracellular signals or intracellular mechanisms such
as phosphorylation. Fos transcription factors are believed
to act as a molecular switch that leads to downstream con-
sequences including altered protein expression, structural
changes, and ultimately function (see [166]). Drugs of abuse
have the ability to increase the expression of this family
of transcription factors and while this occurs primarily
in the NAcc, changes may also occur in the PFC, VTA,
and amygdala, among others ([167], see [168]). Following
chronic exposure to cocaine self-administration (18 days,
for 4 hours a day) the expression of cFos, FosB, and ΔFosB
is altered in a regional and temporal manner [169]. The
expression of ΔFosB protein is the greatest in the NAcc;
however, there is no diﬀerence between self-administrating
and yoked animals indicating that this increase occurs in
response to the drug itself and is not dependent on instru-
mental learning [169]. While responses can be sustained for
extended periods [170], the expressions of FosB and cFos,
however, show tolerance following repeated exposure to
cocaine, the latter being dependent on the volition of cocaine
self-administration [169]. Furthermore, prior exposure to
cocaine “primes” the inducibility of the FosB gene resulting
in an increase in both mRNA and protein expression in
the NAcc following subsequent reexposure after an extended
period of withdrawal [171]. Indeed it is changes to the
expression of ΔFosB that have been associated with addiction
the most, especially as ΔFosB is estimated to mediate 25% of
the changes to gene expression in the NAcc following chronic
cocaine exposure specifically in the MSNs of the direct
pathway (see [168, 172]). FurthermoreΔFosB accumulates in
reward-associated nuclei in response to drugs of abuse where
it is believed to play a role in mediating reward (via induction
of the GluA2 subunit of AMPA receptors) [173], acquisition,
and motivation [174].
Following extinction training Fos may play a greater
role in addiction than ΔFosB as its expression is increased
in the basolateral amygdala and prelimbic PFC during this
period [175]. This occurs in the absence of changes to GluA2.
Furthermore, the induction of Fos transcription factors is
heavily influenced by CREB which can be induced by a
drug and binds to the FosB promoter. In mice, if CREB and
serum response factor are deleted from the NAcc, exposure
to cocaine fails to result in the normal induction of ΔFosB
and animals become less sensitive to cocaine’s rewarding
eﬀects [176, 177]. However, deletion of CREB alone has no
eﬀect on ΔFosB and actually enhances cocaine rewarding
eﬀects. Furthermore, serum response factor appears to
be involved in mediating ΔFosB activity following stress-
related responses [176] highlighting the complex intracel-
lular regulation of these factors in response to, at least,
cocaine.
3.3. Epigenetics. While changes to the underlying gene struc-
ture may increase an individual’s predisposition to addictive
behaviours, new insights indicate that specific mechanisms
regulate posttranslational modifications of gene expression.
This enables the control of heritable changes to phenotypes
that are not dependent on changes in the genetic code itself
(see [178, 179]). So termed “epigenetics”, these modifications
occur via remodelling of chromatin structure incorporat-
ing the influence of environmental stimuli. Consequently,
enhanced or suppressed transcription of genes to proteins
is influenced by the summation of posttranslational modi-
fications to histones or changes to DNA itself independent of
the DNA sequence. These modifications limit access of tran-
scription factors and thus result in altered gene expression
(see [180] for a review). While every cell contains the same
DNA sequence, it is believed that epigenetic mechanisms act
to regulate the specific pattern of genes expressed at any given
time thus serving to establish and maintain diﬀerent gene
expression programs in specific cell types and imprinting a
phenotype on that cell [181]. Epigenetics can act to regulate
gene functions in a reversible but stable manner including
whether the expression of a gene is turned on or oﬀ. This
includes priming genes following exposure to a drug, such
that subsequent exposures result in increased mRNA or
protein expression of the gene product [171]. Epigenetic pro-
cesses therefore permit long-term regulation of gene function
which does not require mutagenic mechanisms. Epigenetic
mechanisms are also believed to play a key role in mediating
personality traits as indicated from identical twin studies
[182] and influence of gene-environment interactions.
Our knowledge regarding the role of epigenetics in
addictive behaviours is relatively new (see [178] Table 2 for
extensive list of epigenetic changes following exposure to
drugs of abuse). A current hypothesis is that exposure to
drugs of abuse results in stable epigenetic modifications that
alter gene expression and neuroadaptive changes seen during
the transition to, and maintenance of, an addicted state. It is
also believed that these epigenetic changes act to perpetuate
relapse following periods of abstinence [183–185]. Of the
possible epigenetic processes known DNA methylation and
posttranslational modification of histones are currently the
best understood. However, while both these processes have
the ability to mediate downstream neuroadaptive changes,
they do not appear mutually exclusive.
3.3.1. DNA Methylation. DNA methylation occurs via the
addition of a methyl group in a reaction catalysed by a
group of enzymes called DNA methyltransferases (DNMTs),
of which there are currently 3 members (see [186]). DNMT
3A and 3B are involved in the transfer of methyl groups
to naked or unmethylated regions of DNA and are referred
to as de novo DNMTs. In contrast, DNMT 1 methylates
hemimethylated DNA in the precise manner that mimics
the methylation patterns present prior to replication. Thus
DMNT 1 is responsible for maintaining methylation during
replication and can also repair DNA methylation being
referred to as a maintenance DNMT. DNA methylation can
occur at any one of the 4 possible bases (i.e., cytosine,
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adenine, guanine, and thymine); however, methylation of
cytosine appears the most stable. In the case of cytosine,
methylation occurs primarily (but not exclusively) when it
is positioned next to guanine in the DNA sequence (CpG)
(see [178]). Methylation in promoter regions, which often
contain large numbers of CpG repeats called CpG islands (up
to 3,000 base pairs in length), for example, inhibits the ability
of transcription factors to bind to the gene. This also involves
recruitment of methyl-binding domain containing proteins
such asMeCP2 to form corepressor complexes which leads to
chromatin compaction and gene repression (see [178, 179]).
DNAmethylation can occur in a region and drug-specific
manner [187] and is believed to play a key role in synaptic
plasticity, learning, and memory formation [188]. Acute
cocaine exposure in mice upregulates the mRNA expression
for DNMT 3A and 3B in the NAcc [189]. For DNMT 3A this
occurs within 1.5 hours after treatment, with both DNMT 3A
and 3B being upregulated after 24 hours. Repeated exposure
for 7 days does not alter DNMT expression but at both
time points, however, DNA hypomethylation is present at
the FosB promoter. This corresponds to an upregulation of
FosB in the NAcc and aﬀects the appearance of behavioural
sensitization [189]. Interpretation of epigenetic changes,
especially in human studies, should note that age alone may
alter DNAmethylation levels asmethylation of DAT increases
with age [190]. There also appears to be the possibility of an
overlap between epigenetic modifications such as diﬀerential
CpG methylation and SNPs, with methylation of SNPs for
prodynorphin in the PFC being associated with alcohol
dependence in humans [191].
3.3.2. Histone Modification. Histones are alkaline proteins
which form the chief components of chromatin. They com-
prise 6 classes subdivided into 5 families (H1/5, H2A, H2B,
H3, H4, and H5) with H1 and H5 considered linker histones
(to the DNA) and the remainder known as core histones (two
copies each) around which DNA is wrapped. Modifications
to N-terminal histone tails or globular domains include
acetylation, phosphorylation, ubiquitination, sumoylation,
methylation, and polyADP-ribosylation, with acetylation
being the most well understood (see [179] for more informa-
tion regarding histone phosphorylation and methylation).
Acetylation weakens or disrupts histone to DNA contacts,
causing the chromatin to relax, which increases access of
transcription factors to the DNA and is thus a sign of active
chromatin [185].
Drugs of abuse induce specific modifications to histones,
this can be gene and region specific and can be heavily
influenced by whether the drug is presented either acutely
or chronically. This can further be impacted by the duration
of exposure, with subsequent and diﬀerent modifications
being observed during periods of withdrawal [178, 179].
Genomewide studies suggest that acute exposure to cocaine,
for example, activates most genes acutely by acetylation at H4
[192]. Chromatin immunoprecipitation assays in rats have
shown that in the NAcc this can occur at the cFos promoter
within 30 minutes but appears transient, disappearing by 3
hours, and nonresponsive to subsequent exposures which
is constant with the time course of induction of cFos
expression following cocaine. In contrast to the findings for
cFos, chronic exposure to cocaine increases and sustains H3
acetylation at the BDNF and Cdk5 promoter for 1–7 days
after the final dose [192], supporting the observation of
chronic exposures activating most genes by acetylation at
H3 (see [180]). Studies of genomewide chromatin changes
in the NAcc in mice have shown that more genes are
acetylated at H3 compared to H4 following repeated cocaine
administration, with few gene promoters displaying acety-
lation at both H3 and H4 [193]. This indicates that while
both modifications may regulate gene expression following
cocaine, they act independently on distinct populations of
genes.
Epigenetic changes may also result in neuroadaptive
changes that consequently cause altered behaviour. Repeated
exposures to cocaine in mice reduces the levels of H3
lysine 9 dimethylation in the NAcc [194]; the authors
suggest that histone methylation may play a critical role in
neuroadaptations in the NAcc that mediate cocaine pref-
erence. While drug-induced histone modifications appear
relatively stable, persisting in the PFC for up to 2 weeks
into straight abstinence [180], they do not appear global
such that changes to acetylation at one family can also be
diﬀerentially regulated across genes. Acetylation of H3 (K9–
14) for the immediate early gene EGR1 is reduced and
maintained for up to 10 days of abstinence following chronic
cocaine, while H3 acetylation of neuropeptide Y is transiently
increased at day 1 of withdrawal returning to base line by
day 10 [113]. In both cases, H3 acetylation mimics mRNA
expression for EGR1 and neuropeptide Y, respectively. In
the VTA, 7 days of forced abstinence from cocaine increases
protein levels for BDNF and exon I transcripts which are
associated with increased H3 and CREB-binding protein
activity [62]. However, interpreting the role of acetylation in
addictive behaviours becomes complicated by the fact that
epigenetic changes can precede their downstream results by
some time. Chronic self-administration of cocaine in rats
increases acetylation of the promoter for BDNF in the NAcc
within 24 hrs after the last exposure [192]. However, BDNF
protein is not elevated until a week after cocaine withdrawal
[65], suggesting that epigenetic changes may play a role in
priming genes for subsequent induction.
Understanding the impact of epigenetic modifications
is complicated by the fact that these modifications are
potentially reversible and can bemediated by other processes.
For example, acetylation is highly regulated by two families of
enzymes, namely, histone acetyltransferases (HATs), which
promote acetylation by catalysing the addition of acetyl
groups, and histone deacetylases (HDACs) which remove
acetyl groups. These enzymes integrate intracellular signals
to regulate activation or suppression of gene programs (see
[195] for review). HDACs are able to modulate cocaine’s
eﬀects on locomotor activity [192] and, when an HDAC
inhibitor is infused into the shell of the NAcc in rats,
responding for cocaine increases, while overexpression of
HDAC4 in the same region reduces responding [196].
Together this would suggest that HDACs have the ability
to influence the motivational aspects of self-administration,
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at least for cocaine. Exposure to a drug is also suﬃcient
to diﬀerentially aﬀect the expression of these regulatory
enzymes which may result in either activation (i.e, via
DARPP-32 or CREB-binding protein (CBP)) or suppression
(i.e., via HDAC or DNMT 3A) of transcription [197].
Mutant mice that have depleted levels of the HAT CBP
show less behavioural sensitization to cocaine following 10
days of exposure, which correlates with decreased histone
acetylation and FosB expression (though FosB expression
was normal prior to cocaine) [198]. Prior drug exposure
may also prime the response to another drug of abuse by
enhancing the transcription of FosB, through inhibition
of HDAC, and enhancing the depression of LTP in the
NAcc [199]. There is also a close association between
the regulation of gene expression by transcription factors
or via epigenetic modification with interplay between the
activating or repressing eﬀects of a transcription factor and
chromatin-mediating enzymes at certain genes. For example,
phosphorylation of CREB recruits CBP. As CBP is a HAT it
is able to acetylate histones thus increasing gene expression,
while also being a transcriptional coactivator regulating the
expression of ΔFosB (see [200]). ΔFosB can also regulate
lysine dimethyltransferases, which mediate histone methyla-
tion and contribute to dendritic spine plasticity and cocaine
preference [194].
While only DNA methylation and histone acetylation
are presented in this paper and are considered separate
identities, crosstalk exists between these factors making
epigenetic modifications highly complex and integrated.
Consequently, it is very unlikely that only a single process
occurs at any one given time point. Transcriptome profiling
in postmortem brain tissues from the amygdala and frontal
cortex in 17 alcoholics reported both DNA hypomethylation
and histone H3K4 trimethylation [201]. These processes can
occur concomitantly at the same gene. Chronic intermittent
exposure to ethanol results in DNA methylation [202]
and H3K9 acetylation of the 5′ regulatory region of the
gene for GluN2B, the latter occurring predominately during
withdrawal and coincides with a significant decrease in H3K9
methylation [203]. Furthermore, H3K9 methylation can
direct subsequent DNA methylation [204] with decreased
histone methylation corresponding to altered gene expres-
sion in the PFC (especially those genes coding for cell
adhesion molecules and transcription factors) and altered
behaviour in adult rats following 12 days of cocaine at
ascending concentrations during adolescence [205].
3.4. Noncoding RNA. Conventionally DNA produces mRNA
transcripts which are then translated into proteins. However
it appears that the majority of genomic DNA is transcribed
into what is now referred to as noncoding RNA (ncRNA).
This allows RNA itself to act as a regulator of subsequent
mRNA translation. It is becoming increasingly apparent that
ncRNAs play distinct roles in determining many cellular
processes by modulating inhibition or activation of gene
expression in processes including regulation of cell cycling,
diﬀerentiation, signal transmission, apoptosis, synaptic plas-
ticity, and response to DNA damage (see Figure 1 in [206]).
To date, ncRNAs include microRNA (miRNA), endogenous
small interfering RNA (siRNA), short hairpin RNA (shRNA),
piwi-interacting RNA, small nucleolar RNA, ribosomal RNA,
splice junction-associated promoter-associated short RNA,
termini-associated short RNA, and large intergenic ncRNA,
among others [206, 207]. These ncRNAs can be classified as
either small (<400 nucleotides) or large (>400 nucleotides)
and contribute to infrastructure (i.e., ribosomal RNA) or
regulatory (i.e., miRNA) mechanisms. They can interact at
the level of either DNA, RNA, or proteins themselves aﬀect-
ing transcription, translation and the stability of mRNA,
alternative splicing and epigenetic regulation [206, 207].
The expression of ncRNAs can be regulated in an activity-
dependentmanner, and while there is increasing information
about the role ncRNAs play in neurodegenerative disorders
and disease, the function of many of these ncRNAs is
not well defined especially in vivo. Indeed their role in
addictive behaviour is relatively unexplored though there is
growing evidence that they may play significant roles. For
example, in rats introduction of shRNAs in the NAcc shell
is suﬃcient to downregulate endogenous CREB expression
and reduce cocaine reinforcement [45]. As our ability to
utilise ncRNAs to determine the functional roles of pathways
is increasing, ncRNAs appear to provide a potential avenue
for therapeutic intervention (see Section 3.4.2 below). This
is in light of new technology incorporating the use of
recombinant adenoassociated virus vectors to introduce
ncRNAs into specific neural pathways. These vectors can be
injected intravenously to target and inhibit selected ncRNAs
thus increasing mRNA levels of their targets and permit-
ting investigation of their function [208]. Their unique
feature includes long-term stability having been shown to
maintain inhibition of ncRNAs for at least 25 weeks [208].
Furthermore, these vectors overcome the prior limitations
requiring repeated administration and route of delivery
seen with complimentary chemically modified anti-ncRNA
oligonucleotides which have been used in the past.
3.4.1. MicroRNA. MicroRNAs are short endogenous ncR-
NAs (ranging in size from 19 to 25 nucleotides) that coordi-
nate the fine tuning of posttranscriptional gene expression,
first discovered for their role in development [209]. Long
primary miRNA transcripts are initially processed to short
pre-miRNAs which are transported from the nucleus and
cleaved to short nucleotide sequences. Via interactions with
the enzyme Dicer, which facilitates the formation of the
RNA-induced silencing complex, precursor miRNAs become
functionally binding to complementary sequences of 3′-
untranslated regions of their target mRNAs. This results in
the repression of translation of mRNAs and either inhibits
protein synthesis or induces sequence-specific degradation of
mRNA at the posttranscriptional level [210–213]. Evidence
also suggests that miRNAs, such as miR373 which is involved
in the regulation of E-cadherin, may also act to enhance gene
expression [214]. There are currently hundreds of known
miRNAs and their complexity is amplified by the fact that any
one miRNA has multiple targets, and more than one miRNA
can regulate the same mRNA [215].
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MiRNAs have clear functions in development [209]
including neurogenesis, with further roles in synaptogenesis
and plasticity. This includes the regulation of receptor
expression [216] and function [217], as well as regulating
LTP and LTD [218], especially in hippocampal-mediated
memory and learning [219]. Indeed the induction of either
LTP or LTD is suﬃcient to evoke changes in the expression of
numerous hippocampalmiRNAs [220].While the expression
of most miRNAs in the hippocampus may be regulated by
either LTP or LTD and occurs with a similar expression
profile, they display diﬀerent expression dynamics including
the time at which expression occurs [220].
Since miRNAs (1) mediate dopaminergic responses
[221], (2) alter receptor expression (including glutamate
receptors) [222], (3) have the ability to respond rapidly
to cellular signals to regulate local mRNA expression, and
(4) display subcellular localisation, including dendrites, they
are believed to play a key role in the conversion of drug-
induced synaptic plasticity to long-term adaptations. Both
the expression of dopamine D1 receptors [221] and the
fine tuning of dopaminergic processes and dopaminergic-
mediated behaviours such as locomotion [223] can be
regulated by specific miRNAs. Furthermore, drugs of abuse
can alter gene expression via miRNA-mediated pathways
[224], with miRNAs implicated in mediating the eﬀects
of cocaine [225], alcohol (see [226, 227] for extensive
review), and nicotine [224]. It has been shown that nicotine
specifically alters the expression of up to 25 miRNAs
including an increased expression of miR-140 which inhibits,
among others, DNMT 1 [224]. Acute alcohol up regulates
miR-9, which has been linked to tolerance via its eﬀects
on posttranscriptional reorganization in the mRNA for
calcium- and voltage-activated potassium (BK) channels
[228].
However, exposure to a drug can have diﬀerential eﬀects
on miRNA expression. Chronic cocaine treatment in rats
can both up- (miR-181a) and down- (miR-124 and let-
7d) regulate the expression of miRNAs in a miRNA- and
region-specific manner [225], including in the NAcc, dorsal
striatum, and hippocampus. It can also both decrease
and increase over 30 miRNAs specifically localised to
post-synaptic densities [229]. The three miRNAs men-
tioned above have the ability to directly aﬀect drug-related
behaviours such as attenuating (miR-124 and let-7d) or
enhancing (mi-181a) a CPP to cocaine when expressed in the
NAcc [230]. Furthermore, expression of miR-124 and let-7d
alters BDNF and dopamine receptor expression at the pro-
tein level [225], with miRNA-induced alterations in BDNF
resulting in altered dendritic spine morphology [231]. The
miR-124 also targets the transcription factor RE1-silencing
transcription factor (REST) thus repressing gene expression
in a double negative feedback loop manner [232]. REST
can also suppress BDNF indicating that there is a complex
interaction on the inhibition of BDNF that can occur at both
the translational (miRNA) and transcriptional (REST) level.
While miRNAs can alter the expression of neurotrophins,
miRNAs can also be induced by neurotrophins. In neonatal
rat cortical neurons, the presence of BDNF upregulates the
precursormiRNA-132, a target and inhibitor of CREB, which
is suﬃcient to aﬀect neuronal morphogenesis and increase
neurite outgrowth [233]. Via a diﬀerent CREB-mediated
mechanism, miR-212 expression in the dorsal striatum alters
the stimulatory eﬀects of cocaine [234]. Using lentivirus
the authors show that overexpression of striatal miR-
212 decreases the motivation of animals to self-administer
cocaine, while antisense oligonucleotide inhibition of the
same miRNA increases cocaine intake [234], suggesting that
deficits in miR-212 signalling may increase an individual’s
vulnerability to addiction.
It is also becoming evident that miRNAs can mediate
chromatin remodelling through the regulation of factors
such as MeCP2, a DNA-binding protein that can compact
chromatin structure independent of DNA modification such
as methylation [235]. Activation of MeCP2 may not only
result in repression of transcription [236] but may also
activate transcription through CREB [237]. Chronic ethanol
for 10 days can alter the expression of 26 miRNAs in
cultured cortical neurons, 20 of these being diﬀerentially
expressed should ethanol treatment only continue for 5
days followed by 5 days of abstinence, 3 of these having
the common target MeCP2, suggesting that cessation of
drug influence is an independent factor regulating miRNA
expression [238]. Furthermore, MeCP2 and miR-212 can
form homeostatic interactions in the dorsal striatum that
alter cocaine’s eﬀects on BDNF levels [239]. Thus altered
expression of miRNAs appears suﬃcient to drive specific
aspects of addictive behaviours via intricate mechanisms
which may occur via direct regulation of protein synthesis
at the synapse or via interaction with transcription or
epigenetic factors at the cellular level. This can result in the
activation of CREB, which promotes transcription, or REST,
which suppresses transcription, of the same target; both
of these factors can also regulate miRNA expression [240].
Therefore it is hypothesised that it is the combined actions
of these three elements (miRNA, CREB, and REST) that
ultimately regulate gene expression via coordinated feedback
mechanisms.
3.4.2. SiRNA. SiRNAs are small (19–23 nucleotides) dou-
ble stranded ncRNAs that associate with multicomponent
nucleases called RNA-induced silencing complexes. This
complex guides the siRNA to the complementary mRNA
region resulting in sequence-specific gene silencing. Unlike
antisense oligonucleotides, which can block the translation
of a single copy of mRNA before being degraded, siRNAs
can regulate multiple mRNA transcripts, are 100 times more
eﬀective than antisense oligonucleotides, and are sustained
for a relatively long duration [241]. Consequently, siRNAs
(and shRNAs) are beginning to emerge in the field of
neuroscience due to their therapeutic potential. This has
initially been shown for treatment of cancer where antisense
oligodeoxynucleotides mimicking siRNA/shRNA function
can be produced to downregulate gene expression (see
[242]). With respect to the same application for treating
addiction, siRNAs have been used to stably transfect HEK-
MOR cells in vitro to silence the expression of CREB and
Ets-like protein-1, both targets for activated ERK1/2 [243].
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In doing so the cellular responses following stimulation
of the cells with morphine and following withdrawal were
significantly altered. SiRNAs against the GluN2B subunit
of NMDA receptors have also been injected into the NAcc
and VTA in rats [244]. The authors used this technique
to show that downregulation of the GluN2B subunit for
up to 14 days is suﬃcient to abolish reward behaviour (as
measured by CPP) following chronic morphine exposure but
not behavioural sensitization to repeated exposures, though
this occurred only when siRNAs were injected into the NAcc
and not the VTA. Indeed, a recent study by Bonoiu and
colleagues used nanotechnology to produce a gold labelled
nanorod-DARPP-32 siRNA complex in an attempt to target
dopaminergic signalling in the brain [245]. While their
experiments were conducted ex vivo, they were able to
show uptake of these antagonist nanoplexes in dopaminergic
neurons which resulted in functional gene silencing of
dopamine and cAMP-regulated phosphoprotein-32 for up
to 1 week after transfection and other key downstream
eﬀector molecules of this pathway including ERK and phos-
phoprotein phosphatase 1. The nanoplexes did not appear
to result in cytotoxicity and were shown to transmigrate
across an in vitro blood brain barrier model [245]. While
numerous considerations exist for implementing ncRNAs
in RNA interference-based gene therapy including route of
delivery, kinetics, and oﬀtarget eﬀects (see [246] for extensive
review), they nonetheless provide the potential for site-
specific approaches for treating drug addiction. Indeed they
have already been used to knock down gene expression
for TrkB within the NAcc in rats which is associated with
inhibition of a CPP and reinstatement to cocaine [66] and
with lentivirus mediated shRNA knock-down experiments
indicating that CaMKIIalpha expression in the NAcc (shell)
plays a role in the motivation to self-administer cocaine
[196].
3.5. Optogenetics. To date dissection of the microcircuitry
controlling aspects of addictive behaviours has, in part, relied
heavily on the use of lesion or electrical stimulation experi-
ments, pharmacology studies employing exogenous applica-
tion of antagonists/agonists administered either peripherally
or localised to a discrete nucleus, or the generation of knock-
out or knock-in animals, some requiring further genetic
manipulation and temporal activation via secondary drug
application or electrical stimulation (see [247, 248]). Each
of these approaches provides information relative to the
mechanisms mediating addiction but contain unavoidable
drawbacks. Antagonist experiments are dose and time
dependent, require drugs to be degraded before normal
activity can be returned, may produce secondary eﬀects at
other targets, and do not allow the generation of defined pat-
terns of spike wave activity. Knock-out/in animals may result
in secondary compensatory changes as a result of altered
gene expression throughout development. While conditional
knockout/ins provide some improvement to this issue, the
eﬀects of altered gene expression cannot be independently
regulated. Electrical stimulation is complicated by the fact
that many cells are deeply embedded in dense heterogeneous
brain tissue making selective stimulation diﬃcult based on
microelectrode placement and may result in costimulation
of fibre networks within the targeted region. The technique
often requires numerous electrodes at once which may result
in secondary tissue injury.
New advances in technology have seen a growing
application for optogenetics in neuroscience research. The
concepts on which our current use of optogenetics is based
were first described by Boyden and colleges in two papers
originating in 2005 [249] and 2006 [250]. The technology
was subsequently reviewed in 2006 [251] with the first in vivo
demonstration of the ability to alter behaviour in rodents
via excitation of motor cortical neurons by the same group
in 2007 [252]. Hailed as the method of the year by Nature
in 2010 [253], optogenetics combines theories from optics,
genetics, and bioengineering to study the function of intact
neuronal circuits to gain greater insight into neural dynamics
and behaviour. Optogenetics also appears to have many
advantages as it has high temporal precision being utilised
in awake behaving animals. This enables causal connections
between specific neuronal populations and behaviour output
to be investigated allowing distinction between the function
of neuronal microcircuitry. It has been demonstrated in C.
elegans that this technology can be used to induce the release
of specific neurotransmitters at neuromuscular junctions to
alter behaviour [254]. Thus via optogenetic stimulation in
this model release of acetylcholine induces body contraction,
whereas stimulation of GABA release results in body elon-
gation. Optogenetic probes are primarily versions of opsins,
seven-transmembrane ion channels that are light sensitive
and subsequently translocate ions across plasma membranes
upon stimulation. There are 3 main classifications of these
probes based on the results following stimulation, those that
result in depolarization (i.e., channelrhodopsin-2 (ChR2)),
those that result in hyperpolarisation (i.e., halorhodopsin)
and those that alter intracellular signalling (see [247]).
3.5.1. Neuronal Excitation. To date the majority of work has
focused on optogenetics using the green algal protein ChR2,
a light activated nonspecific cation ion channel. ChR2 can be
introduced at the level of the cell body and, once transfected
into the membrane of the target cell, will induce cell firing
upon stimulation. Alternatively, ChR2 can be introduced
to neuronal axons and synaptic terminals to investigate the
strength of aﬀerent-dependent synaptic transmission and
pathway-specific neurotransmitter release [255]. Targeting is
facilitated via fusion of ChR2 with cell or neurotransmitter-
specific promoters [254] via the use of either transgenic
animals that express the protein of interest under cell-specific
neural promoters or via recombinant retroviral vectors that
are stereotaxically delivered to the target or, to a lesser degree,
using electroporation and anatomical-based gene targeting
(see [247]). Light sources that include halogen lamps, LEDS,
or lasers are then delivered close to the target primarily
through implanted optic fibres (deep tissues) or FEDs if
superficial activation is required. ChR2 is then activated via
the delivery of millisecond (usually 1–5ms) pulses of blue
light (approx. 450–500 nm) thus resulting in a large inward
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flux of sodium, potassium, hydrogen, and calcium ions and
depolarization of the neurons resting membrane potential.
This results in photo stimulation of the target cells resolvable
to single action potentials, without directly aﬀecting the
activity of neighbouring cells (see [256, 257] for in-depth
explanation ofmethods andmethodological considerations).
Recovery and thus pore closing occur within milliseconds
once the light is removed.
Optogenetics holds many features over other techniques
as ChR2 can be genetically targeted to specific defined neural
populations within a single circuit which allows accurate,
fast (within milliseconds), sustained, and reproducible (with
respect to spike firing) stimulation of a large number
of neurons [249, 250]. The magnitude of postsynaptic
currents (i.e., excitation) is controlled by the duration
of the light pulses [250]. Furthermore, as ChR2 requires
continuous illumination of high-intensity light to keep the
channel open, development of new “slow” variants of ChR2
with residue mutations is being developed. These variants
display slower oﬀkinetics, thus delaying channel closing,
and increasing light sensitivity (i.e., they are responsive to
yellow as opposed to blue light) [258]. By using the ChR2
variant to prolong depolarization, the authors found that
they could manipulate long-lasting behavioural alterations
and alter developmental stages in C. elegans. Additional
modifications that can be activated and sustained by one
light intensity and turned oﬀ with a diﬀering light intensity
are also being investigated [247], though modified ChR
channels have not yet been successfully demonstrated in
vivo in mammals. Double mutants of ChR2 have also been
produced, so-called stabilized step-function opsins, these
variants have greater stability in their depolarization and
increased light sensitivity (see [259] for review). A second
channel rhodopsin, VChR1, from the algae Volvox carteri,
has also been utilised to stimulate neurons. The feature
of VChR1 is that it is activated by yellow light (590 nm)
thus increasing the potential of stimulation of deeper brain
areas and co-expression with ChR2 to permit selective
activation of 2 targets within the one region [260]. However,
as deactivation of VChR1 is relatively slow (compared to
ChR2) and VChR1 is also semisensitive to blue light, further
development of VChR1 is needed to optimise its potential
[248].
3.5.2. Neuronal Inhibition. Using similar principles to
those applied to ChR2, modified variants of the bacterially
derived light-sensitive chloride pumps halorhodopsin or
archaerhodopsin-3 can be used in inhibition studies to
silence neuronal activity (see [37, 247]). Halorhodopsin, for
example, once activated by yellow light, results in an inward
flux of chloride ions, hyperpolarization, and neuronal inhibi-
tion (either knockout of single action potentials or blockade
of spiking) [261]. In comparison, archaerhodopsin-3 works
via light-driven proton pumps. Rhodopsin has also been
used to form G-protein coupled receptor chimeras (termed
OptoXRs) [262] that selectively recruit distinct biochemical
signalling pathways in response to light. Initially the
intracellular loops of rhodopsin were replaced with those of
adrenergic receptors α1A or β2. In these OptoXRs, 60 seconds
of green light are suﬃcient to drive downstream signalling
and functional expression. Their validity was tested in the
NAcc in this study where they exerted opposing eﬀects
on spike wave activity with opto-α1A adrenergic receptors,
receptor expressing networks increasing firing, and opto-β2
decreasing firing [262]. Furthermore the authors found
that stimulation of photo-α1A adrenergic receptors in the
NAcc in freely moving mice leads to an increase of CPP to
the environment paired with optical stimulation, specific
to reward-related behaviour and not anxiety or locomotor
activity.
3.6. Optogenetics and Addiction. While the application of
optogenetic technology to the study of addiction shows
great promise, relatively little work incorporating this tech-
nology has been published to date in this field. Indeed
optogenetics has been used to stimulate dopaminergic cell
firing [263] and dopamine release [264] in the striatum,
including the NAcc, in the rat when neurons in either
the VTA [263] or substantia nigra [264] are targeted. In
this second study the authors were able to fine tune and,
respectively, evoke dopamine release ranging from as small
as 50 nM to in excess of 500 nM. The kinetics of this
simulation mirrored that of electrically evoked release with
little observed eﬀect on blood flow as pH was not altered
[264]. The technique has also been used to demonstrate
that dopaminergic neurons in the VTA release not only
dopamine but also glutamate suﬃcient to elicit excitatory
post-synaptic responses in the NAcc [265], suggesting that
the mesocorticolimbic reward system may directly involve
both dopaminergic and glutamatergic responses, the latter
originally thought to play a more modulatory role over this
pathway.
The real benefits of optogenetic technology in addiction
become apparent via the ability to mimic the activation
of circuitry responses to reward-based tasks. Behavioural
modification including induction of a CPP have been
demonstrated via the use of optogenetic stimulation of
dopamine neuronal firing in the VTA [263]. Phasic activation
of these neurons in mice enhances reinforcement in operant
tasks to a food reward and following extinction food-
seeking behaviours can be reinstated via photo stimulation of
dopaminergic neurons in the absence of external cues [266].
Optogenetics has also been used to investigate the causal
relationship between dopaminergic cell firing and reward,
supporting acquisition and maintenance of instrumental
responding to food rewards in genetically modified rat
lines [267]. Kim et al., have shown that a single transient
activation of VTA neurons in mice, mimicking the nature
of responses seen following receipt of a natural reward,
for as little as 200ms following self-initiated nose pokes
is suﬃcient to induce operant reinforcement and poten-
tially drive reinforcement learning [268]. Optogenetics has
also been used to dissect these circuits in the context of
reward. Lobo et al. showed that activation of D1 receptors,
that is, the direct pathway, in the NAcc enhances cocaine
reward whereas activation of D2 receptors in the NAcc
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suppress cocaine reward. The eﬀects of receptor activation
on cocaine reward were shown to be similar to those
mediated by selective deletion of the TrkB receptor and, in
the case of D1, alter downstream markers of BDNF-TrkB
signalling (i.e., pERK) [269]. Together these studies increase
our understanding of the circuit level control of BDNF,
TrkB, and dopamine receptor interactions over cocaine
reward.
In 2010 Witten and colleagues demonstrated the first
behavioural loss of function relative to addiction using
optogenetics in freely moving mice. In this study they
demonstrated that cholinergic interneurons in the NAcc play
a role in mediating a CPP to cocaine with cholinergic neu-
rons being responsive to cocaine and being able to influence
the firing rate of MSNs in this region [270], while still in
its infancy, based on the fact that advances in optogenetic
techniques permit either short or sustained cell excitation
or inhibition, that is, rapidly reversible in awake behaving
animals, it has great potential to increase our understanding
of the processes mediating addiction. This occurs via the
ability to functionally dissect out cell populations and
pathways mediating addictive behaviours and which to target
for intervention strategies. This is enhanced by the fact that
diﬀerent optogenetic probes can be stimulated in light of
diﬀerent wavelengths meaning they can be incorporated at
the same time in the same pathway (see [247] Figure 4
for summary). This occurs without the secondary eﬀects
of the other techniques mentioned above or long-term
injury and/or adaptive mechanism occurring in the cell.
Thus optogenetics holds great potential for application to
systems neuroscience. As reviewed by Tye and Deisseroth,
by using combinations of expression and illumination sites
investigators can determine the eﬀects of activation of local
nuclei and their projection sites, the role of specific cell
populations within this nuclei, or temporal separation of
mixed populations within the same nucleus, or projections to
this nucleus (see [259] Figure 2). Furthermore, optogenetics
can be incorporated into other techniques to improve the
quality of the information obtained. Studies have already
combined optogenetics and electrophysiology techniques in
order to verify the eﬀectiveness of transgene expression, such
that light responsive cells increase and/or decrease spike
wave recordings [271]. These combined techniques can also
enhance the ability to identify the subpopulation of neurons
being recorded and permit noninvasive manipulation of
the activity of cells and/or networks during recording
sessions (see [272]). Optogenetics has also been incorpo-
rated with functional magnetic resonance imaging (fMRI)
(so-called opto-fMRI) using blood oxygenation level-
dependent (BOLD) signals to show optogenetic stimulation
of CaMKIIalpha-expressing excitatory neurons specifically
located in the neocortex or thalamus elicits positive BOLD
signals in adult rats [273]. Similar results are seen when
layer V neocortical neurons are optically stimulated [274].
In these studies, signals were also recorded in downstream
targets highlighting the potential to investigate the circuits
recruited by defined local cell stimulation [273], impor-
tantly this can be successfully carried out awake animals
[275].
4. Summary
This paper has highlighted the complex relationship between
drug induced neuroadaptations in the brain and addictive
behaviours using examples from both human studies and
animal models. These neuroadaptations can occur at the
cellular, molecular, and (epi)genetic level and are hypothe-
sised to be responsible for the transition to, and persistence
of, an addicted state. Following repeated exposure to drugs
of abuse synaptic plasticity is believed to play a key role in
these adaptive changes, at the level of signal transduction,
receptor expression, or synaptic structure. There is growing
evidence that genetics and altered gene expression have
long-term consequences on addictive behaviours. Changes
to gene structure via SNPs may increase an individual’s
vulnerability to becoming addicted should they be exposed
to a drug. There is also a greater understanding of the role of
epigenetic mechanisms and ncRNAs in mediating addiction
as these factors are responsive to drugs of abuse and can
alter the transcription and translation of DNA and RNA,
respectively. New techniques such as optogenetics are also
evolving which permit investigation into the microcircuitry
mediating addictive behaviours. However, addiction is a
highly integrated process complicated by diﬀering pharma-
cological profiles of drugs themselves, individual variation
(either biological or genetic), and environmental factors, all
of which can influence the mechanisms mediating drug-
induced neuroadaptive changes and a person’s vulnerability
to becoming addicted. Thus we face a major contemporary
challenge to elucidate the genetic and molecular identities of
factors implicated in the development andmaintenance of an
addicted state.
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